A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy

A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that is the first approved treatment for spinal muscular atrophy (SMA). The model was built with data from 92 nonhuman primates (NHPs) following intrathecal doses (0.3–7 mg) and characterized the PK in cere...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CPT Pharmacometrics Syst Pharmacol
Main Authors: Biliouris, Konstantinos, Gaitonde, Puneet, Yin, Wei, Norris, Daniel A., Wang, Yanfeng, Henry, Scott, Fey, Robert, Nestorov, Ivan, Schmidt, Stephan, Rogge, Mark, Lesko, Lawrence J., Trame, Mirjam N.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6157691/
https://ncbi.nlm.nih.gov/pubmed/30043511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados